Betta Pharmaceuticals Co., Ltd. Stock

Equities

300558

CNE100002DD9

Pharmaceuticals

End-of-day quote Shenzhen S.E. 18:00:00 2024-06-16 EDT 5-day change 1st Jan Change
37.55 CNY -0.74% Intraday chart for Betta Pharmaceuticals Co., Ltd. +1.73% -27.16%

Financials

Sales 2024 * 3.05B 420M 576M Sales 2025 * 3.65B 503M 690M Capitalization 15.71B 2.17B 2.97B
Net income 2024 * 454M 62.57M 85.86M Net income 2025 * 598M 82.42M 113M EV / Sales 2024 * 5.8 x
Net Debt 2024 * 1.96B 270M 370M Net Debt 2025 * 1.62B 223M 306M EV / Sales 2025 * 4.75 x
P/E ratio 2024 *
34.7 x
P/E ratio 2025 *
26.3 x
Employees 1,961
Yield 2024 *
0.73%
Yield 2025 *
0.71%
Free-Float 51.49%
More Fundamentals * Assessed data
Dynamic Chart
Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares as Cash Dividend (Tax Included) for the Year 2023, Payable on 06 June 2024 CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd. CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Beijing Mabworks Biotech Co., Ltd. announced that it expects to receive CNY 150.000042 million in funding from Betta Pharmaceuticals Co., Ltd. CI
C4 Therapeutics Shares Up 18% After Lung Cancer Drug Application Receives FDA Clearance DJ
Betta Pharmaceuticals Gets Nod for Voronib Tablets' Listing MT
Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023 CI
C4 Therapeutics, Betta Pharmaceuticals Sign Deal to Develop, Commercialize CFT8919 in Greater China MT
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC CI
C4 Therapeutics, Inc. announced that it expects to receive $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd. CI
Betta Pharmaceuticals Co., Ltd. Approves Cash Dividend for the Year of 2022 CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Betta Pharmaceuticals Co., Ltd. Announces Profit Distribution Proposal for 2022 CI
More news
1 day-0.74%
1 week+1.73%
Current month-0.71%
1 month-7.31%
3 months-20.98%
6 months-31.10%
Current year-27.16%
More quotes
1 week
36.27
Extreme 36.27
38.80
1 month
36.27
Extreme 36.27
40.87
Current year
33.11
Extreme 33.11
52.33
1 year
33.11
Extreme 33.11
63.09
3 years
33.11
Extreme 33.11
110.15
5 years
33.11
Extreme 33.11
160.66
10 years
23.19
Extreme 23.19
160.66
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 02-12-31
Chief Executive Officer 60 03-01-06
Director of Finance/CFO 53 15-12-31
Members of the board TitleAgeSince
Chief Executive Officer 60 03-01-06
Director/Board Member 67 19-11-21
Chief Tech/Sci/R&D Officer 60 16-02-27
More insiders
Date Price Change Volume
24-06-16 37.55 -0.74% 2 742 598
24-06-14 37.83 -1.25% 4,712,722
24-06-13 38.31 +0.05% 4,073,831
24-06-12 38.29 +0.34% 4,130,174
24-06-11 38.16 +3.39% 5,073,683

End-of-day quote Shenzhen S.E., June 16, 2024

More quotes
Betta Pharmaceuticals Co Ltd is a company mainly engaged in research, development, production and sales of innovative drugs for the treatment of malignant tumors. The Company's primary product is its self-developed icotinib hydrochloride (Conmana), a small molecule targeted anticancer drug used for the treatment of lung cancer. The Company is also engaged in promotional services, real estate leasing and other businesses.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
37.55 CNY
Average target price
50.98 CNY
Spread / Average Target
+35.75%
Consensus
  1. Stock Market
  2. Equities
  3. 300558 Stock